# Adavosertib

Source: https://onco.cc/drugs/adavosertib/  
OnCo record `adavosertib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adavosertib is an oral serine/threonine kinase inhibitor from AstraZeneca, in registered phase 2 trials for triple-negative breast cancer.

## Summary

Adavosertib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by AstraZeneca, in triple-negative breast cancer. A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Oral serine/threonine kinase inhibitor
- Mechanism: A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family.

## Sources

- ClinicalTrials.gov: trials of Adavosertib: https://clinicaltrials.gov/search?intr=Adavosertib

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.](https://onco.cc/trials/nct03330847/)

---
JSON: https://onco.cc/api/v1/entities/adavosertib.json